B
Braidwell Portfolio holdings
AUM
$2.92B
This Quarter Return
+4.41%
1 Year Return
-4.59%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$3.06B
AUM Growth
+$3.06B
(+0.94%)
Cap. Flow
-$84M
Cap. Flow
% of AUM
-2.74%
Top 10 Holdings %
Top 10 Hldgs %
37.02%
Holding
99
New
15
Increased
19
Reduced
16
Closed
14
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$46M |
| 2 |
Boston Scientific
BSX
|
$38.8M |
| 3 |
Viridian Therapeutics
VRDN
|
$28.7M |
| 4 |
Maravai LifeSciences
MRVI
|
$22.4M |
| 5 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$20.5M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$90.4M |
| 2 |
Glaukos
GKOS
|
$54.3M |
| 3 |
Amgen
AMGN
|
$39M |
| 4 |
Intuitive Surgical
ISRG
|
$34M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
$29.7M |
Sector Composition
| 1 | Healthcare | 54.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Harrow
HROW
$1.38B
| $27.7M | 0.9% |
1,452,538
| – | – |
|
27
Alector
ALEC
$282M
| $24.8M | 0.81% |
4,131,315
+925,000
| +29% | +$5.56M |
|
28
AnaptysBio
ANAB
$630M
| $23.5M | 0.77% |
1,154,423
+181,350
| +19% | +$3.69M |
|
|
DBVT
29
DBV Technologies
DBVT
$249M
| $23M | 0.75% |
1,210,779
| – | – |
|
30
Penumbra
PEN
$10.5B
| $22.7M | 0.74% |
65,844
-41,200
| -38% | -$14.2M |
|
|
31
Maravai LifeSciences
MRVI
$341M
| $22.4M | 0.73% |
+1,804,700
| New | +$22.4M |
|
32
Enanta Pharmaceuticals
ENTA
$189M
| $22.2M | 0.73% |
1,038,310
| – | – |
|
33
HilleVax
HLVX
$105M
| $21.5M | 0.7% |
1,249,246
-370,970
| -23% | -$6.38M |
|
34
Cullinan Oncology
CGEM
$456M
| $20.5M | 0.67% |
+1,908,865
| New | +$20.5M |
|
35
BioCryst Pharmaceuticals
BCRX
$1.74B
| $19.7M | 0.64% |
2,791,880
+846,746
| +44% | +$5.96M |
|
36
Compass Therapeutics
CMPX
$466M
| $18.9M | 0.62% |
5,954,273
+2,706,426
| +83% | +$8.61M |
|
37
RAPT Therapeutics
RAPT
$187M
| $18.4M | 0.6% |
+123,050
| New | +$18.4M |
|
38
Vir Biotechnology
VIR
$765M
| $17.9M | 0.58% |
728,549
+124,513
| +21% | +$3.05M |
|
39
Terns Pharmaceuticals
TERN
$651M
| $16.1M | 0.53% |
1,842,352
-154,703
| -8% | -$1.35M |
|
40
Dyne Therapeutics
DYN
$1.92B
| $15.5M | 0.51% |
1,377,872
| – | – |
|
41
Thermo Fisher Scientific
TMO
$183B
| $14.2M | 0.47% |
+27,300
| New | +$14.2M |
|
42
Rhythm Pharmaceuticals
RYTM
$6.75B
| $13.9M | 0.45% |
+843,087
| New | +$13.9M |
|
43
Danaher
DHR
$143B
| $13.3M | 0.43% |
+62,491
| New | +$13.3M |
|
44
Pulmonx
LUNG
$67.6M
| $13.1M | 0.43% |
999,362
-163,932
| -14% | -$2.15M |
|
45
Repligen
RGEN
$6.54B
| $13M | 0.43% |
+92,000
| New | +$13M |
|
46
Crinetics Pharmaceuticals
CRNX
$3.26B
| $11.7M | 0.38% |
650,312
-1,369,402
| -68% | -$24.7M |
|
47
Replimune Group
REPL
$460M
| $11.3M | 0.37% |
487,520
+413,855
| +562% | +$9.61M |
|
|
SLRN
48
DELISTED
ACELYRIN
SLRN
| $10.5M | 0.34% |
+500,000
| New | +$10.5M |
|
49
Guardant Health
GH
$8.11B
| $9.67M | 0.32% |
+270,000
| New | +$9.67M |
|
50
ALX Oncology
ALXO
$54.6M
| $9.39M | 0.31% |
1,249,900
| – | – |
|